















































































Archives of Medical Research - (2016) -PRELIMINARY REPORT
Does the Serum Metallothionein Level Reflect the Stage
of Testicular Germ Cell Tumor?
Blanka Tariba,a Tanja Zivkovic,a Vlatka Filipovic Marijic,b Marijana Erk,b
Marija Gamulin,c and Alica Pizenta
aAnalytical Toxicology and Mineral Metabolism Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia
bLaboratory for Biological Effects of Metals, Division for Marine and Environmental Research, RuCer Boskovic Institute, Zagreb, Croatia
cDepartment of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia























0188-4409/$ - see fro
http://dx.doi.org/10Increased levels of metallothionein (MT) have recently been found in the blood serum of
men with newly diagnosed testicular germ cell tumors (TGCT). In light of previously
published results, the aim of this study was to investigate the difference in serum MT
levels among patients with different stages of TGCT and compare MT with commonly
used markers (a-fetoprotein, b-human chorionic gonadotropin and lactate dehydroge-
nase). The concentration of total MTwas determined in the serum of 25 men with TGCT
(seminoma or non-seminoma) by differential pulse voltammetry. Serum samples were ob-
tained prior to chemotherapy, after two cycles of chemotherapy and 1 year after chemo-
therapy. A statistically significant difference in MT levels in patients with different stages
of TGCT was observed in the serum of patients with non-seminoma obtained before
chemotherapy. Although not significant, an increase in serum MT levels commensurate
with the disease stage increase was also observed in patients with seminomatous TGCT.
The results indicate that, in combination with the existing markers, MT could be useful
for the identification of the histological type of tumor and stage of the disease before bi-
opsy diagnosis.  2016 IMSS. Published by Elsevier Inc.



















Testicular germ cell tumors (TGCT) are uncommon but
particularly important malignancies as they tend to affect
children and young men, representing the most common
tumor in men aged 15e35 years. Incidence rates have been
increasing over the past 50 years in many industrialized
populations (1,2).
Using the histopathological criteria, TGCT are classified
as seminoma and non-seminoma. In addition, the stage of
tumor at diagnosis is used to determine the extent or spread
of the disease and to help in the diagnosis, treatment and
prognosis of testicular cancer (3). In clinical practice, there
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.1016/j.arcmed.2016.05.005and prognosis of testicular cancer: a-fetoprotein (AFP),
b-human chorionic gonadotropin (b-HCG) and lactate de-
hydrogenase (LDH) (3). Although crucial in the manage-
ment of testicular cancer, these markers are not specific
for testicular cancer and their values are elevated in only
51% of testicular cancer cases (4). It has also been observed
that b-HCG and/or AFP are elevated at relapse in about 2/3
of patients with non-seminoma and in only 1/3 of those
with seminoma, whereas LDH has limited sensitivity, spec-
ificity and positive predictive value and does not add to the
early detection of relapse (5e7). Therefore, there is a need
for additional, minimally invasive biomarkers to optimize
individual treatments of cancer patients.
Metallothioneins (MT) are a group of low molecular
mass, cysteine-rich proteins. Their enhanced synthesis in
rapidly proliferating tissues suggests their crucial role in
normal and neoplastic cell growth (8). Increased levels of
MT in serum have been found in patients with lymphoid-5-2016 10-49-21
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196leukemia, lung carcinoma, thyroid carcinoma, head and
neck cancer (9,10) and prostate cancer (11). In a recently
published study, we found significantly higher levels of
serum MT in patients with newly diagnosed TGCT
compared to healthy volunteers (12). Elevated levels of
serum MT in men with newly diagnosed TGCT make
MT a candidate biomarker for testicular cancer develop-
ment. In an ideal case, a tumor marker reflects the body’s
tumor burden and subsequently increases with progressive
or recurrent disease, decreases with response to treatment,
and normalizes with remission (13). Therefore, in the cur-
rent study, we evaluated serum MT levels among patients
with different stages of TGCT in the samples obtained
before chemotherapy (I), after two cycles of chemotherapy
(II) and 1 year after chemotherapy (III) and compared
serum MT levels with those of commonly used tumor























The study population consisted of 25 men (age:
18e49 years), non-smokers, with newly diagnosed TGCT
ascertained by the Department of Oncology at the Univer-
sity Hospital Centre, Zagreb, Croatia. Based on histological
reports, the patients were classified as having seminoma or
non-seminoma. After orchiectomy, patients were treated
with two, three or four cycles of standard chemotherapy,
every 3 weeks with bleomycin, etoposide, cisplatin (bleo-
mycin 30 units iv weekly on days 2, 9 and 16; etoposide
100 mg/m2 iv on days 1e5; cisplatin 20 mg/m2 iv on days
1e5) depending on the stage of the disease (1, 2 or 3).
Venous blood was sampled from each patient before any
type of treatment (I), after two cycles of chemotherapy
(II) and 1 year after chemotherapy (III). Levels of serum tu-
mor markers AFP, b-HCG and LDH were determined as
part of routine biochemical tests used for differential diag-
nosis and surveillance of patients.ARCMED2089_proof ■ 2
Table 1. Concentrations of metallothionein (MT) and levels of serum tumor ma
seminoma and non-seminoma before chemotherapy (I), after two cycles of chem
MT (mg/mL) AFP (mg/L)
All patients (n 5 25)
I 0.55 (0.27e1.21) 5.0 (1.40e19,032.0)
II 0.64 (0.25e1.08) 3.41 (1.0e81.0)
III 0.26 (0.18e0.74) 3.0 (0.74e12.0)
Seminoma (n 5 11)
I 0.67 (0.27e1.21) 2.70 (1.40e11.0)
II 0.65 (0.25e0.94) 3.75 (1.0e9.0)
III 0.26 (0.20e0.70) 3.10 (1.20e12.0)
Non-seminoma (n 5 14)
I 0.48 (0.30e1.16) 7.0 (2.0e19,032.0)
II 0.59 (0.25e1.08) 3.31 (2.0e81.0)
III 0.26 (0.18e0.74) 2.86 (0.74e5.0)Before entering the study, all subjects were informed
about the aim and experimental details and provided signed
consent for voluntary participation. The study was per-
formed in accordance with the ethical principles of the
Declaration of Helsinki and approved by the institutional
Ethics Committee.
Metallothionein Assay
MT was determined in heat-treated blood serum to enable
the analysis of MTs as heat stable proteins. The concentra-
tion of total MT was determined by differential pulse vol-
tammetry according to a modified Brdicka procedure
(14,15) as described in Tariba et al. (12).
Statistical Analysis
Statistical analyses were performed using Statistica 12 for
Windows (StatSoft Inc., Tulsa, OK). In order to normalize
the distribution of the MT concentration data, a logarithmic
transformation was applied. One-way analysis of variance
(one-way ANOVA) was used to evaluate the difference in
serum MT levels between patients with different stages of
TGCT (stage 1, 2 or 3). Spearman’s rank correlation (r,
p) was calculated for the associations between MT and
AFP, b-HCG and LDH levels. Data were considered statis-
tically significant at p ! 0.05.Results and Discussion
The discovery and validation of additional markers in com-
bination with current markers is important for improving
the diagnosis and management of testicular cancer.
Although AFP, b-HCG and LDH are the most commonly
used serum markers for the management of TGCT, they
are not very sensitive and specific because their values
can also be increased in the presence of other tumors
(16,17). AFP is expressed in 50e70% of non-
seminomatous TGCTs, whereas in patients with pure9-5-2016 10-49-21
rkers (AFP, b-HCG and LDH) (median and range) in patients with
otherapy (II) and 1 year after chemotherapy (III) Q1
b-HCG (IU/L) LDH (U/L)
1.20 (0.0e14,101.0) 201.0 (96.0e1,726.0)
0.0 (0.0e16.0) 179.0 (127.0e250.0)
0.0 (0.0e1.20) 167.0 (119.0e219.0)
0.0 (0.0e11.0) 203.0 (96.0e665.0)
0.0 179.0 (127.0e236.0)
0.0 168.0 (138.0e190.0)
2.60 (0.0e14,101.0) 201.0 (120.0e1,726.0)
0.0 (0.0e16.0) 178.5 (138.0e250.0)




























































































309seminoma an elevated AFP raises suspicion of the presence
of non-seminomatous elements. Elevated serum b-HCG
levels are typically present in both seminomas and non-
seminomas, whereas LDH is a less specific marker but
has an independent prognostic value in men with advanced
testicular cancer (4,18). The concentration of MT found in
our study and the levels of commonly used serum tumor
markers (AFP, b-HCG and LDH) in patients with semino-
ma and non-seminoma obtained before chemotherapy (I),
after two cycles of chemotherapy (II) and 1 year after
chemotherapy (III) are presented in Table 1. The levels of
AFP, b-HCG and LDH in the serum of our subjects ob-
tained 1 year after chemotherapy were found to be normal
in both types of TGCT (according to the American Joint
Committee on Cancer, 2010).
The values obtained for MT in TGCT patients (before
and after therapy) were significantly higher than those
measured in the serum of healthy volunteers (median
and range 0.412 (0.230e0.687) mg/mL) (published in
Tariba et al. 2015). In patients with germ cell tumors,ARCMED2089_proof ■ 29
Figure 1. Concentrations of metallothionein (MT) (log transformed) in serum of
obtained before chemotherapy, after two cycles of chemotherapy and 1 year afte
with non-seminoma. Full dot, square and triangle represent mean values, wherea
tistically significant at p ! 0.05.the level of commonly used tumor markers usually re-
flects the stage of the disease (3,19). Figure 1 indicates
an increase in the serum MT concentration commensurate
with cancer stage increase (stage 1, 2 or 3), when all pa-
tients (Figure 1A), patients with seminoma (Figure 1B)
and patients with non-seminoma (Figure 1C) were consid-
ered. According to the results of one-way ANOVA, there
is a statistically significant difference in serum MT levels
across different stages of TGCT in the samples of patients
with non-seminoma obtained before chemotherapy. In the
available literature there are no similar results for compar-
ison. The existing data on MT levels in testicular cancer
patients come from the studies that investigated the levels
of MT using immunohistochemical staining in TGCT
specimens obtained after radical orchiectomy. The most
recent results of a meta-analytical approach, which com-
prises the data from these studies for the evaluation of im-
munohistochemically determined MT as a cancer
biomarker, found no association between MT staining
and tumor stage in TGCT (20).-5-2016 10-49-21
patients with different stage of testicular germ cell tumor (stage 1, 2 or 3)
r chemotherapy. (A) All patients. (B) Patients with seminoma. (C) Patients






































































































410We found a significant positive correlation between MT
and AFP levels in all patients (r 5 0.594, p! 0.04) and in
seminoma patients (r 5 0.886, p ! 0.02) only in the sam-
ples obtained after two cycles of chemotherapy, whereas no
significant correlation was found between these parameters
before chemotherapy or 1 year after chemotherapy. No sig-
nificant correlation was found between MT levels and b-
HCG and LDH. The lack of significant correlation between
the levels of MT and serum tumor markers in newly diag-
nosed TGCT patients suggests that the diagnostic value of























Our results indicate the potential of serum MT as an addi-
tional marker that could provide helpful information for
adequate management and treatment of TGCT, including
early diagnosis, determination of histological type and
stage of the disease. Nevertheless, based on the limited re-
sults, we cannot unambiguously assert that serum MT is a
suitable marker for TGCT. The low number of patients
may be considered a limiting factor for the power of the
study. In particular, the lack of statistical significance be-
tween groups might be attributed to the inclusion of a
limited number of patients. Additional studies including a
larger number of subjects as well as patients with disease
relapse are needed to further elucidate the significance of
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